Company
Headquarters: Ahmedabad, India
Employees: 247
₹5.53 Billion
INR as of July 1, 2024
US$66.3 Million
| Company | Market Cap (USD) |
|---|---|
| Lilly | $808.65 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $450.89 B |
| Johnson & Johnson | $350.63 B |
| Merck | $318.75 B |
Sakar Healthcare Limited researches, develops, manufactures, and markets pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectable SVP in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of 155 formulations in approximately 22 therapeutic areas, such as antacid, antimalerial, anticoagulant, laxative, anthelmintic, bronchodilator, anaesthetic, antidepressant, sedative, adrenergic, anti-infective, diuretics, oxytocic, analgesic, antiemetic, antipsychotic, antifungal, PPI, anticonvulsant, anti-inflammatory, antihistamine, and multi vitamins, as well as oncology drugs. The company also exports its products to approximately 53 countries, including South East Asia, Asia, Africa-Anglo and Francophone, MENA countries, America, and European markets. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedabad, India.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Sakar Healthcare Ltd has the following listings and related stock indices.
Stock: NSE: SAKAR wb_incandescent